Stressgen (VSE: SSB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (201)	10/28/2002 6:41:42 PM
From: Heat Shock	Read Replies (1) of 236

Hi Nigel, As you know, biotech patent lawsuits are par for the course. In the recent conference call Stressgen CEO Dan Korpolinski was asked why Antigenics would file oppositions which have virtually no chance of succeeding. He said "I have NO idea". There is a FAQ on the patents on Stressgen's site: stressgen.com Antigenics has had a run of bad luck in being associated with Milken and then with Waksal. I think they may be really overextended in the number of expensive clinical trials they have ongoing. They lucked in 100 million dollars, or whatever it was, by IPOing in the biotech boom, but it's all too easy to spend that much. I think their therapy will work, but being an "HSP complex", might be delayed by requests for more information somewhere along the way about its exact composition. Antigenics and Stressgen can simultaneously succeed. BTW conference call slide show PDF is available on this page. Lots of discussion of trial results. stressgen.com Heat.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next